January 24, 2008 - Mauna Kea Technologies, an in-vivo cellular imaging company, announced the closing of a $30 million financing round, the proceeds of which will be used to expand commercialization of the company’s Cellvizio technology in the U.S. and Europe, as well as to advance additional clinical applications of the platform.
Founded in 2000, Mauna Kea Technologies develops and markets Cellvizio, a fundamentally new imaging approach that improves patient care by reportedly eliminating the need for unnecessary biopsies and enhances the diagnosis of a broad range of diseases via in vivo cellular imaging.
“This financing will enable us to expand our U.S. presence and advance our clinical program to validate Cellvizio’s utility in improving the diagnosis and treatment of disease found in the esophagus, colon, stomach, bile duct as well as the distal lungs, ” said Sacha Loiseau, Ph.D., founder, president and chief executive officer of Mauna Kea Technologies.
Mauna Kea also announced that it has changed the name of its U.S. operations to Cellvizio Inc. to strengthen brand awareness.
For more information: www.maunakeatech.com